Actelion launches VALCHLOR (mechlorethamine) gel 0.016% in the US

20-11-2013 Business Wire HealthComments (0)

ActelionPharmaceutical

Actelion launches VALCHLOR (mechlorethamine) gel in the US for patients with stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top